RusnanoMedInvest and Domain Associates Invest $21 Million in Neurology Company Marinus Pharmaceuticals
1/7/2013 10:28:28 AM
More...
|
Marinus Pharmaceuticals Experimental Epilepsy Treatment Shows Promise in Open-Label Extension Study
12/21/2011 7:39:41 AM
More...
|
Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
4/21/2011 6:59:08 AM
More...
|
Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
4/13/2011 11:20:54 AM
More...
|
Marinus Pharmaceuticals Issued Patent for Ganaxolone
4/7/2011 6:59:18 AM
More...
|
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
7/29/2009 8:51:39 AM
More...
|
Marinus Pharmaceuticals Raises $20 Million in Series B Financing
4/10/2009 6:57:23 AM
More...
|
Marinus Pharmaceuticals Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
3/3/2009 8:22:10 AM
More...
|
Marinus Pharmaceuticals Completes Two Phase 2 Milestones for Ganaxolone in Epilepsy Marinus Closes Phase 2 Trials for Infantile Spasms and Completes Enrollment for Phase 2 Trial in Adult Partial Complex Seizures
10/7/2008 9:43:09 AM
More...
|
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8/5/2008 6:20:20 AM
More...
|
|